278 related articles for article (PubMed ID: 3041925)
21. Activation of T lymphocytes for the adoptive immunotherapy of cancer.
Sussman JJ; Shu S; Sondak VK; Chang AE
Ann Surg Oncol; 1994 Jul; 1(4):296-306. PubMed ID: 7850528
[TBL] [Abstract][Full Text] [Related]
22. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
23. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
Spiess PJ; Yang JC; Rosenberg SA
J Natl Cancer Inst; 1987 Nov; 79(5):1067-75. PubMed ID: 3500355
[TBL] [Abstract][Full Text] [Related]
24. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
25. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
26. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.
Topalian SL; Rosenberg SA
Acta Haematol; 1987; 78 Suppl 1():75-6. PubMed ID: 3124451
[TBL] [Abstract][Full Text] [Related]
27. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
Takai N; Tanaka R; Yoshida S; Hara N; Saito T
Cancer Res; 1988 Apr; 48(8):2047-52. PubMed ID: 3258182
[TBL] [Abstract][Full Text] [Related]
28. Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2.
Shimizu K; Okamoto Y; Miyao Y; Yamada M; Ushio Y; Hayakawa T; Ikeda H; Mogami H
J Neurosurg; 1987 Apr; 66(4):519-21. PubMed ID: 3494108
[TBL] [Abstract][Full Text] [Related]
29. [LAK cells and cancer].
Taguchi T; Kimoto Y
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
[TBL] [Abstract][Full Text] [Related]
30. Current approaches to the adoptive immunotherapy of cancer.
Yang JC; Rosenberg SA
Adv Exp Med Biol; 1988; 233():459-67. PubMed ID: 3265581
[TBL] [Abstract][Full Text] [Related]
31. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
32. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
33. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
34. Cancer immunotherapy: current status of treatment with interleukin 2 and lymphokine-activated killer cells.
van Haelst-Pisani CM; Pisani RJ; Kovach JS
Mayo Clin Proc; 1989 Apr; 64(4):451-65. PubMed ID: 2654502
[TBL] [Abstract][Full Text] [Related]
35. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
Mazumder A; Rosenberg SA
J Exp Med; 1984 Feb; 159(2):495-507. PubMed ID: 6141211
[TBL] [Abstract][Full Text] [Related]
36. Lymphokine-activated killer (LAK) cells can be focused at sites of tumor growth by products of macrophage activation.
Migliori RJ; Gruber SA; Sawyer MD; Hoffman R; Ochoa A; Bach FH; Simmons RL
Surgery; 1987 Aug; 102(2):155-62. PubMed ID: 3497459
[TBL] [Abstract][Full Text] [Related]
37. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.
Atzpodien J; Kirchner H
Klin Wochenschr; 1990 Jan; 68(1):1-11. PubMed ID: 2407894
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
39. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
40. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Rosenberg SA
Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
